RECURRENT THYROID GLAND CARCINOMA
Clinical trials for RECURRENT THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: targeted drug takes aim at HRAS gene
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib given before surgery in 30 people with thyroid cancer that has a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and make surgery more successful. Participants take selpercatinib for a shor…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New combo therapy shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tested whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has spread or come back. It included 34 adults whose cancer had a specific gene change (RAS mutation) or no changes in RAS or RAF genes. The goa…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug cocktail trial aims to tame tough tumors
Disease control OngoingThis early-phase trial tests the safety and best doses of two drugs (bevacizumab and temsirolimus) given alone or with other medicines (valproic acid or cetuximab) in people with advanced cancer or certain non-cancerous diseases that are hard to treat. The goal is to find the hig…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: RECURRENT THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 04:33 UTC